Physician profile
Stacey Lopez
NPI 1134769292
$18,643.11
in general payments reported to CMS, 2019-2025
30 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,067 · 2022: $4,561 · 2023: $3,742 · 2024: $4,571 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,743.20 |
| Education | $270.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,999.24 | 2021-2025 | |
| Genzyme Corporation | $2,207.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,795.52 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $1,322.48 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $1,155.16 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,043.76 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $996.19 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $893.67 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $804.37 | 2023-2025 | Zoryve |
| Ucb, INC. | $599.23 | 2021-2025 | Bimzelx, Briviact |
| Galderma Laboratories, L.P. | $595.58 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $552.79 | 2021-2025 | Cabtreo, Siliq, Jublia |
| Sun Pharmaceutical Industries INC. | $480.57 | 2021-2024 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $444.76 | 2023-2024 | Vtama |
| Pfizer INC. | $432.28 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $398.78 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $314.22 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $258.74 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $214.39 | 2021-2025 | Opzelura |
| Almirall LLC | $205.44 | 2022-2024 | Klisyri |
| Sanofi-Aventis U.S. LLC | $164.99 | 2022-2024 | |
| Organon LLC | $164.54 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $146.01 | 2021 | |
| Journey Medical Corporation | $137.51 | 2021-2022 | |
| Epi Health, LLC | $99.22 | 2022 | |
| Abbott Laboratories | $76.89 | 2024 | Proclaim |
| Paratek Pharmaceuticals, INC. | $65.41 | 2024-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.21 | 2023-2024 | Cyltezo |
| Medimetriks Pharmaceuticals, INC. | $28.46 | 2023-2025 | Neo-Synalar |
| Tempus Ai, INC | $15.95 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.